Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging.

MLA

Lowe, S. L., et al. “Donanemab (LY3002813) Phase 1b Study in Alzheimer’s Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging.” The Journal of Prevention of Alzheimer’s Disease, vol. 8, no. 4, 2021, pp. 414–24. EBSCOhost, https://doi.org/10.14283/jpad.2021.56.

APA

Lowe, S. L., Duggan Evans, C., Shcherbinin, S., Cheng, Y.-J., Willis, B. A., Gueorguieva, I., Lo, A. C., Fleisher, A. S., Dage, J. L., Ardayfio, P., Aguiar, G., Ishibai, M., Takaichi, G., Chua, L., Mullins, G., & Sims, J. R. (2021). Donanemab (LY3002813) Phase 1b Study in Alzheimer’s Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging. The Journal of Prevention of Alzheimer’s Disease, 8(4), 414–424. https://doi.org/10.14283/jpad.2021.56

Chicago

Lowe, S L, C Duggan Evans, S Shcherbinin, Y-J Cheng, B A Willis, I Gueorguieva, A C Lo, et al. 2021. “Donanemab (LY3002813) Phase 1b Study in Alzheimer’s Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging.” The Journal of Prevention of Alzheimer’s Disease 8 (4): 414–24. doi:10.14283/jpad.2021.56.